Pharmaceuticals

PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from two Phase 1/2a clinical trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutics being developed …

Molecular Docking results Molecular docking was conducted using the PyRx virtual screening tool integrated with AutoDock Vina, a highly efficient molecular docking and virtual screening software. The 3D structures of …

A strategic collaboration formed to raise awareness that all diabetics taking hypoglycemic drugs should take glucagon. Preferably, a preparation that can be used immediately chicago and arlington, virginia, January 21, …